期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗治疗恶性淋巴瘤的进展 被引量：2

Advances of rituximab in the treatment of malignant lymphoma
下载PDF
导出
摘要 利妥昔单抗(人源化CD20单克隆抗体,商品名美罗华)是首个批准用于治疗表达CD20恶性淋巴瘤的单克隆抗体,广泛应用于低度恶性非霍奇金淋巴瘤(NHL)、侵袭性NHL,亦试用于霍奇金淋巴瘤(HL)及其他B细胞性恶性肿瘤。利妥昔单抗联合细胞毒性药物的疗效已在B细胞NHL的有关临床试验中得到证实。目前该药已被批准用于侵袭性淋巴瘤和惰性淋巴瘤的一线治疗,其维持治疗滤泡性淋巴瘤亦得出鼓舞人心的结果。利妥昔单抗已成为治疗B细胞性恶性淋巴瘤的重要手段之一。 The chimeric anti-CD20 monoclonal antibody rituximab is the first humanized mono- clonal antibody approved for patients with malignant lymphoma with CD20 expression. Rituximab has been approved to treat indolent non-Hodgkin＇s lymphoma and aggressive non-Hodgkin＇s lymphoma as first-line medication. Other indications of this agent used to manage Hodgkin＇s lymphoma and other B-cell malignancies were in the clinical trial stage. The adjunctive therapy of rituximab with cytotoxic agents or cytokines has been impressed in many clinical studies. The maintenance treatment of indolent non-Hodgkin＇s lymphoma with rituximab also yielded promising results. Rituximab has become the part of standard therapy for B cell non-Hodgkin＇s lymphoma.
作者 黄慧强 蔡清清
机构地区 中山大学肿瘤医院内科
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第21期1883-1888,共6页 Chinese Journal of New Drugs
关键词 恶性淋巴瘤 单克隆抗体 利妥昔单抗 malignant lymphoma monoclonal antibody rituximab
分类号 R730.53 [医药卫生—肿瘤] R969.4 [医药卫生—药理学]
  • 相关文献

参考文献33

  • 1FISHER RI,GAYNOR ER,DAHLBERG S,et al.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J].N Engl J Med,1993,328 (14):1002-1006.
  • 2MCLAUGHLIN P,GRILLO-LOPEZ AJ,LINK BK,et al.Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program[J].J Clin Oncol,1998,16 (8):2825-2833.
  • 3DAVIS TA,GRILLO-LOPEZ AJ,WHITE CA,et al.Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:safety and efficacy of re-treatment[J].J Clin Oncol,2000,18(17):3135 -3143.
  • 4COIFFIER B,BOUAFFIA F,THIEBLEMONT C,et al.Rituximab re-treatment in B-Cell lymphoma patients:efficacy and toxicity in 59 patients treated in one center[J].Blood,2002,100:a1390.
  • 5BERINSTEIN NL,GRILLO-LOPEZ AJ,WHITE CA,et al.Association ofserum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma[J].Ann Oncol,1998,9(9):995-1001.
  • 6GHIELMINI M,SCHMITZ SF,COGLIATTI SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule[J].Blood,2004,103(12):4416 -4423.
  • 7PIRO LD,WHITE CA,GRILLO-LOPEZ AJ,et al.Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma[J].Ann Oncol,1999,10 (6):655-661.
  • 8CZUCZMAN M,GRILLO-LOPEZ AJ,LOBUGLIO AI,et al.Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission[J].Blood,2003,102:a1493.
  • 9CZUCZMAN MS.Immunochemotherapy in indolent nonHodgkin'slymphoma[J].Semin Oncol,2002,29 (2 Suppl 6):S11-S17.
  • 10HITR C,SCHUELER F,SCHWENKE C,et al.High percentage of molecular remissions in advanced stage follicular lymphoma (FL) patients treated with chemoimmunotherapy in comparison to chemotherapy alone[J].Blood,2002,100:a1402.

二级参考文献26

  • 1Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 2Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 3Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 4The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 5Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 6Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.
  • 7Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4) :235-242.
  • 8McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond totreatment program [J]. J Clin Oncol, 1998,162833.a four-dose(8):2825-2833.
  • 9Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD [J]. Ann Intern Med,1986, 104(6) : 757-765.
  • 10Elias L,Portlock CS,Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide,adriamycin, vincristine and prednisone (CHOP) [J]. Cancer,1978.42(4) : 1705-1710.

共引文献55

同被引文献33

引证文献2

二级引证文献8

中国新药杂志
2006年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部